Bionovo announces publication of positive trial outcomes for Menerba Bionovo.

The outcomes from Menerba’s first Stage 2 medical trial support the function of estrogen receptor beta as a novel focus on for dealing with menopausal symptoms. Large clinical trials, like the HERS and the WHI, elucidated serious safety worries connected with hormone therapy. These outcomes have resulted in a dramatic drop in the usage of estrogens, said Isaac Cohen, cEO and chairman of Bionovo, Inc. Because of this, it is essential to develop safer options for dealing with menopausal symptoms presently affecting 30 million ladies in the US.The analysis showed that long-term methamphetamine make use of changes endogenous proteins in drug users, leading to aberrant immune responses. As a result, increased levels of proinflammatory cytokines-proteins involved in immune response-may be a previously unrecognized molecular system for the development of cardiovascular disorders such as for example vasculitus, an irritation of the arteries. Our previous studies demonstrated that methamphetamine can glycate or add sugars to proteins, said Scripps Analysis Professor Kim Janda, who conducted this scholarly study in collaboration with Scripps Analysis Associate Professor Tobin Dickerson and other colleagues.